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Objective: To describe associations between total and regional body fat mass loss and reduction of
systemic levels of inﬂammation (C-reactive protein (CRP) and interleukin-6 (IL-6)) in obese, older adults
with osteoarthritis (OA), undergoing intentional weight loss.
Design: Data come from a single-blind, 18-month, randomized controlled trial in adults (age: 65.6 ± 6.2;
Body mass index (BMI): 33.6 ± 3.7) with knee OA. Participants were randomized to diet-induced weight
loss plus exercise (D þ E; n ¼ 150), diet-induced weight loss-only (D; n ¼ 149), or exercise-only (E;
n ¼ 151). Total body and region-speciﬁc (abdomen and thigh) fat mass were measured at baseline and 18
months. High-sensitivity CRP and IL-6 were measured at baseline, six and 18 months. Intervention effects
were assessed using mixed models and associations between inﬂammation and adiposity were
compared using logistic and mixed linear regression models.
Results: Intentional total body fat mass reduction was associated with signiﬁcant reductions in log-
adjusted CRP (b ¼ 0.06 (95% CI ¼ 0.04, 0.08) mg/L) and IL-6 (b ¼ 0.02 (95% CI ¼ 0.01, 0.04) pg/mL).
Loss of abdominal fat volume was also associated with reduced inﬂammation, independent of total body
fat mass; although models containing measures of total adiposity yielded the best ﬁt. The odds of
achieving clinically desirable levels of CRP (<3.0 mg/L) and IL-6 (<2.5 pg/mL) were 3.8 (95% CI ¼ 1.6, 8.9)
and 2.2 (95% CI ¼ 1.1, 4.6), respectively, with 5% total weight and fat mass loss.
Conclusions: Achievement of clinically desirable levels of CRP and IL-6 more than double with intentional
5% loss of total body weight and fat mass. Global, rather than regional, measures of adiposity are better
predictors of change in inﬂammatory burden.
Clinical Trial Registration Number: NCT00381290.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Inﬂammation is a necessary response of the immune system to
acute infection or trauma; however, a prolonged inﬂammatory: K.M. Beavers, Wake Forest
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ternational. Published by Elsevier Lstate has detrimental health effects1. Old age is associated with
higher circulating levels of inﬂammatory biomarkers2, and chronic,
low-grade inﬂammation is involved in the pathophysiology of a
number of aging-related conditions3, including osteoarthritis (OA)4.
Indeed, levels of several inﬂammatory biomarkers are higher in
older adults with OA compared to those without5. Therapies that
control or reduce inﬂammation may be effective for prevention
and/or improvement of OA and its debilitating symptoms.
Obesity is a strong modiﬁable risk factor for OA6, and is asso-
ciated with signiﬁcantly higher levels of C-reactive protein (CRP)
and interleukin-6 (IL-6)7, two inﬂammatory biomarkers implicated
in the onset and progression of OA4,8. Interventions that reduce
excess body weight also reduce inﬂammatory burden9, especiallytd. All rights reserved.
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state of low-grade inﬂammation10. For overweight and obese in-
dividuals, achievement of at least 10%weight loss most consistently
improves the inﬂammatory proﬁle11e13; yet, the amount of weight
and fat mass loss necessary to achieve a clinically desirable level of
inﬂammation in this population is unknown. Moreover, whether
there is a greater beneﬁt of loss of adipose tissue from speciﬁc
depots/regions on inﬂammation is not known. Fat stored in ectopic
regions (such as the abdominal viscera and thigh muscle) is asso-
ciated with higher circulating levels of CRP and IL-6 independent of
total fat mass14e16, suggesting that greater reduction of fat in these
regions may be associated with greater improvement in the in-
ﬂammatory proﬁle.
The primary purpose of this study was to present the effect of an
intensive lifestyle-based weight loss intervention on CRP and IL-6
in obese, older adults with knee OA. Secondarily, we explored
whether the relationship observed between fat loss and inﬂam-
matory burden was region speciﬁc. Lastly, we tested whether a 5%
loss of total body mass and fat mass was associated with increased
odds of achieving clinically desirable levels of CRP and IL-6. Clinical
cut-points of <3.0 mg/L and <2.5 pg/mL of CRP and IL-6, respec-
tively, were empirically selected based on cardiovascular disease
(CVD)17 and disability18 risk prediction thresholds. We hypothe-
sized that: (1) randomization to dietary-induced weight loss would
signiﬁcantly reduce inﬂammatory burden; (2) reduction in CRP and
IL-6 would be most strongly associated with loss of ectopic (i.e.,
visceral, intermuscular) rather than global or subcutaneous fat
stores; and (3) a 5% loss of total body mass and fat mass would be
signiﬁcantly associated with achievement of clinically desirable
levels of systemic inﬂammation.Method
Study design
We performed an ancillary analysis of data collected as part of
the Intensive Diet and Exercise for Arthritis (IDEA) trial
(NCT00381290), a single-blinded, 18-month, randomized
controlled trial comparing the effects of exercise-only (E), intensive
dietary-induced weight loss (D), or D þ E on OA symptoms in 454
older adults with knee OA19. The Wake Forest University Health
Sciences Institutional Review Board approved this study (IRB#
00000602), all study participants gave written informed consent to
participate, and main study ﬁndings are published10. As previously
reported, both diet groups lost signiﬁcantly (P < 0.01) more weight
than the E group. Over 18-months, the D þ E group lost an average
of 11.4% (10.6 kg) and the D group lost 9.5% (8.9 kg); the E group lost
1.8 kg, or 2.0%, of baseline body weight. Further, compared with E
participants, knee compressive forces were lower in D
participants and IL-6 levels were lower in D and D þ E
participants10.Study participants
Detailed participant inclusion and exclusion criteria are pub-
lished19. The original study sample consisted of 454 ambulatory,
community-dwelling persons age 55 years with: (1) grade IIeIII
(mild to moderate) radiographic tibiofemoral OA or tibiofemoral
plus patellofemoral OA of one or both knees; (2) 27.0  Body mass
index (BMI)  40.5 kg/m2; and (3) a sedentary lifestyle, deﬁned as
not participating in a program that incorporates more than 30 min
per week of formal exercise within the past 6 months. The sample
for the present study include all IDEA participants with CRP and IL-
6 measurements at baseline (n ¼ 450).Interventions
Both the D and D þ E groups received the same dietary inter-
vention, consisting of group and individual nutrition education and
behavioral sessions, as well as an individualized dietary prescrip-
tion plan providing an energy-intake deﬁcit of 800e1000 kcals/day
to reach a study goal of 10% of baseline weight lost. The E-only
group was not counseled to restrict caloric intake during the study
intervention period. The D þ E and E groups received the same
exercise intervention, consisting of aerobic walking (15 min),
strength training (20 min), a second aerobic phase (15 min), and
cool-down (10 min), 3 days per week. During the ﬁrst 6 months,
participation was center-based; afterward, participants could
remain in the facility program, opt for a home-based program, or
combine the two.
Measurements
Body composition
All body composition measures were collected at baseline and
18 months. BMI was measured in all participants and calculated as
mass (measured in kilograms on a standard calibrated scale)
divided by height squared (measured in meters). Baseline whole
body fat mass (kg) was measured by dual-energy X-ray absorpti-
ometry (DXA; Delphi A™, Hologic (Waltham, MA)) in 396 partici-
pants (n ¼ 58 participants declined baseline DXA due to concerns
over radiation exposure and/or lack of time) with a coefﬁcient of
variation of 1.2% and following the manufacturer's recommenda-
tions for patient position and scan protocols and analysis.
Computed tomography (CT) scans, using a GE 16-slice Light
Speed Pro, quantiﬁed abdominal (intramuscular, subcutaneous,
visceral) and thigh (intermuscular, subcutaneous) fat volume (cm3)
in a random subset of IDEA participants pre and post-intervention
(n¼ 116). Participants were placed supine in the scanner with arms
above the head and legs ﬂat. Abdominal scanning technique was
120 KVp, 320 mA, 2.5-mm-thick slices, a helical pitch of 6.25 mm/
rotation, and a gantry speed of 0.5 s. Scanning covered the lower
abdomen, including the umbilicus and lower lumbar vertebra, us-
ing a 50-cm scan and display ﬁeld that included the entire girth. Fat
depots were deﬁned by technicians segmenting volumes based on
established anatomical boundaries. Subcutaneous fat was deﬁned
as outside the abdominal wall musculature; visceral fat as within
the inner aspect of the abdominal wall; intermuscular fat as within
the abdominal and paraspinal musculature. Thigh scans were
conducted at 120 KVp, 350 mA, 10-mm helical with a pitch of
11.25 mm/rotation and a gantry speed of 0.8 s. The femur, from
head to medial condyle, was measured and divided into three equal
lengths. Measurements were performed on 50-mm-long slices
centered at the boundary of the proximal and middle third of the
femur.
Inﬂammatory biomarkers
Blood samples were successfully collected at baseline in 450
participants in the early morning (between 7 and 9 AM) after a 12-
h fast (see Fig. 1). Six-month (n ¼ 366 for CRP and n ¼ 368 for IL-6;
n ¼ 84 and 82 loss to follow-up, respectively) and 18-month
(n ¼ 350 for both CRP and IL-6; n ¼ 100 loss to follow-up) blood
samples were collected at least 24 h after the exercise session, and
blood sampling was postponed (1e2 weeks after recovery of all
symptoms) in the event of an acute respiratory, urinary tract, or
other infection. All blood was collected, processed, divided into
aliquots, stored locally at 80C, and batch analyzed using previ-
ously published methods20. Brieﬂy, high-sensitivity IL-6 assays
were run using Quantikine enzyme-linked immunosorbent kits
from R&D systems (Minneapolis, MN) and high-sensitivity CRP was
Fig. 1. IDEA Consort diagram.
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agnostics Products Corporation, Los Angeles, CA).Statistical analysis
Baseline characteristics are presented on all participants with
baseline inﬂammatory biomarker data (n ¼ 450). Sample means
and standard deviations are estimated for the continuous
descriptive characteristics, and count and proportions were calcu-
lated for the discrete descriptive characteristics overall and by
intervention group. For all inferential models, continuous outcomes
were checked for approximate normality, and a log-transformation
was applied for right-skewed inﬂammation variables. Regression
model assumptions were checked using residual quantileequantile
plots for continuous outcomes to ensure appropriate ﬁt. The
intervention effect for variables collected at only baseline and 18
months (CT and DXA outcomes) was estimated using a one-way
analysis of variance model for unadjusted estimates, and adjusted
estimates were based on an analysis of covariance model that
included baseline BMI, gender, and baseline values of the outcome
to minimize model variance bias as speciﬁed by the IDEA analytic
plan19. For outcomes collected at six and 18 months (body mass,
BMI, CRP, and IL-6), a mixed linearmodel was utilized to account for
within-subject variability assuming a ﬁrst-order autoregressive
covariance structure, and either no covariates (unadjusted) or
baseline BMI, gender, and baseline values of the outcome (adjusted)
were included in the model. Participants with missing follow-up
visit data were excluded from visit-speciﬁc analyses, and prior
publication indicate that attrition was likely unrelated to random-
ization assignment19. Overall group comparisons were performed
at a 0.05 level, and when group comparisons were signiﬁcant,pairwise comparisons between arms were deemed signiﬁcant at a
Bonferroni-adjusted 0.0167 level.
Associations between baseline body composition and inﬂam-
mation data were performed using linear regression adjusting for
randomization group, race, gender, and age. To determine the as-
sociation between change in adiposity (resulting from intentional
weight loss) and change in inﬂammatory biomarkers, analyses
were limited to D and D þ E arms, and all associations were
adjusted for randomization arm, race, gender, age, and baseline CRP
or IL-6 values. In both baseline and change analyses, model ﬁt was
compared using Akaike's Information Criteria (AIC) with a model
limited to participants who had all adiposity measurements to
ensure a comparable sample size across all models. Logistic
regression was used to estimate the odds (95% Wald conﬁdence
intervals) of attaining clinically desirable biomarker values based
on a 5% change in body mass, as weight loss of this magnitude is
considered clinically meaningful21. A similar threshold was selected
for fat mass loss. Analyses were conducted for all groups and
weight loss arms only, adjusted for randomization group, baseline
BMI, gender, and baseline inﬂammation status. Tests of association
were performed assuming a Type I error rate of 0.05. All statistical
analyses were performed using SAS software, version 9.3 (SAS
Institute, Inc., Cary, NC).Results
Participant baseline characteristics
Baseline demographic characteristics of the study sample
(n ¼ 450) are presented in Table I. Brieﬂy, participants were
65.6 ± 6.2 year of age, 71% were women, and 83% were of Caucasian
Table I
Baseline descriptive characteristics according to treatment group
Participant characteristics Exercise (n ¼ 150) Diet (n ¼ 149) Diet þ Exercise (n ¼ 151) Overall (n ¼ 450)*
Age (years) 65.5 ± 6.4 65.8 ± 6.2 65.5 ± 6.0 65.6 ± 6.2
Female, n (%) 108 (72) 105 (70) 108 (72) 321 (71)
White, n (%) 123 (82) 128 (86) 123 (81) 374 (83)
Weight (kg) 92.3 (14.5) 93.4 (15.2) 92.9 (14.4) 92.3 (14.7)
BMI (kg/m2) 33.5 ± 3.7 33.7 ± 3.8 33.5 ± 3.7 33.6 ± 3.7
Self-reported comorbidities, n (%)
Hypertension 89 (60) 90 (62) 91 (61) 270 (61)
Cardiovascular disease 135 (92) 19 (13) 11 (8) 42 (10)
Diabetes 18 (12) 18 (12) 23 (15) 59 (13)
DXA-acquired adiposity measures (n ¼ 396)
Total body fat mass (kg) 36.9 ± 7.7 36.4 ± 7.3 37.0 ± 8.2 36.8 ± 7.7
Percent total body fat (%) 40.0 ± 7.0 39.9 ± 6.6 40.1 ± 6.7 40.0 ± 6.7
CT-acquired adiposity measures (n ¼ 177)
Total abdominal fat volume (cm3) 8625.4 ± 2031.5 8028.6 ± 1731.9 7921.0 ± 1991.8 8194.4 ± 1940.5
Abdominal visceral fat volume (cm3) 3282.1 ± 1390.8 3018.9 ± 1348.9 2895.4 ± 1222.8 3066.3 ± 1324.9
Abdominal subcutaneous fat volume (cm3) 5064.7 ± 1603.9 4779.9 ± 1330.1 4772.0 ± 1443.3 4873.8 ± 1463.7
Abdominal intermuscular fat volume (cm3) 278.5 ± 118.9 229.8 ± 78.4 253.6 ± 115.3 254.4 ± 107.4
Total thigh fat volume (cm3) 988.1 ± 310.4 910.3 ± 286.0 937.9 ± 308.5 946.0 ± 302.1
Thigh intermuscular fat volume (cm3) 32.5 ± 17.7 30.9 ± 17.0 32.5 ± 21.8 32.0 ± 18.9
Thigh subcutaneous fat volume (cm3) 955.6 ± 309.2 879.4 ± 285.7 905.4 ± 306.7 914.0 ± 300.9
CRP (mg/L) 8.7 ± 11.5 10.1 ± 13.1 7.6 ± 8.8 8.8 ± 11.3
IL-6 (pg/mL) 3.0 ± 2.1 3.2 ± 2.3 3.2 ± 2.22 3.1 ± 2.2
Data are presented as means ± SD or n (%).
* Inﬂammatory biomarkers assessed on 450 (out of 454) IDEA participants. DXA and CT-acquired adipositymeasures are only available on a subset of IDEA participants (total
n ¼ 396 and 177, respectively).
Table II
Unadjusted and adjusted 18-month treatment effects on regional fat mass
Regional fat
volume
measures
Exercise Diet Diet þ Exercise Overall
P-value*
Estimate SE Estimate SE Estimate SE
Total abdominal fat (cm3)
Unadjusted 8592.8 382.2 6813.4 358.7 6342.2 377.1 <0.01*
Adjusted 8151.4 244.5 6858.4 228.5 6802.3 234.7 <0.01*
Abdominal visceral fat (cm3)
Unadjusted 3082.6 211.8 2394.2 198.8 2276.2 209.0 0.02y
Adjusted 2981.9 112.8 2406.3 106.7 2433.1 107.0 <0.01*
Abdominal subcutaneous fat (cm3)
Unadjusted 5233.5 265.6 4198.9 249.3 3852.4 262.1 <0.01*
Adjusted 4944.5 140.8 4239.1 137.6 4158.6 144.0 <0.01*
Abdominal intermuscular fat (cm3)
Unadjusted 276.8 17.6 220.3 16.5 213.6 17.3 0.02y
Adjusted 252.4 9.9 229.4 9.3 218.7 9.5 0.04y
Total thigh fat (cm3)
Unadjusted 1391.8 91.0 1132.3 84.3 1071.3 88.6 0.03y
Adjusted 1322.4 66.8 1160.6 65.6 1151.5 67.0 0.11
Thigh intermuscular fat (cm3)
Unadjusted 46.8 4.8 40.2 4.4 40.4 4.6 0.54
Adjusted 48.8 3.7 41.3 3.5 41.7 3.6 0.25
Thigh subcutaneous fat (cm3)
Unadjusted 1345.0 89.3 1092.1 82.7 1030.8 86.9 0.03y
Adjusted 1274.8 63.9 1122.4 63.0 1112.4 64.3 0.12
Unadjusted estimates are based on a one-way ANOVA at 18 months. Model-
adjusted estimates control for gender, baseline BMI, and baseline outcome mea-
sure. In cases where statistical signiﬁcance is noted.
* Indicates E differs signiﬁcantly from D þ E and D.
y Indicates Dþ E differs signiﬁcantly from E (all pairwise comparisons P < 0.0167).
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(BMI ¼ 33.6 ± 3.7 kg/m2; percent body fat ¼ 40.0 ± 6.7%), and
median CRP and IL-6 levels were modestly elevated (5.25 (IQR 2.10,
10.70) mg/L and 2.31 (IQR 1.59, 3.94) pg/mL, respectively) at
baseline, with 67% (n ¼ 303) of participants with CRP levels
3.0 mg/L and 46% (n ¼ 208) with IL-6 levels 2.5 pg/mL.
Intervention effects on adiposity and inﬂammation
As previously reported10, both diet groups lost signiﬁcantly
more weight and fat mass than the E group (both P < 0.001).
Change in body mass for participants with baseline and follow-up
data in the current study sample (n ¼ 339) was 9.3 ± 0.6 kg,
8.4 ± 0.6 kg, and 1.3 ± 0.6 kg for the D þ E, D and E groups,
respectively, with no difference observed between D þ E and D
(P ¼ 0.32). Likewise, D þ E and D groups had an 18% and 15%
reduction, respectively, in total body fat mass over the 18-month
intervention, while negligible change in total body fat mass (~1%)
was observed in the E-only group.
All abdominal fat depots (e.g., total, visceral, subcutaneous, and
intermuscular) were signiﬁcantly reduced in the D þ E and D
groups, compared to E, at 18-months (all P < 0.05; Table II). Simi-
larly, 18-month total, intermuscular, and subcutaneous thigh fat
estimates were lower in the D þ E and D groups, compared to E,
although adjusted results did not reach statistical signiﬁcance.
After adjustment for visit, gender, baseline BMI, and baseline
biomarker value, a signiﬁcant treatment effect on inﬂammatory
burden was observed. As previously reported10, D þ E and D par-
ticipants presented with lower 18-month IL-6 than E participants
[2.7 (0.2) and 2.7 (0.2) for D þ E and D, vs 3.2 (0.2) pg/mL for E;
P < 0.01]. 18-month CRPwas also reduced in the Dþ E and D groups
[5.3 (SE ¼ 1.1) and 4.2 (1.1), respectively vs 6.9 (1.1) mg/L for E;
P < 0.01]; see Fig. 2, and both diet groups had twice the odds of
achieving clinically desirable levels of CRP at 18-months (i.e.,
<3.0 mg/L) compared with the E group (P ¼ 0.02). Although the
odds of achieving IL-6 <2.5 pg/mL was trending in a similar di-
rection [1.5 (0.8e2.7) and 1.6 (0.9, 2.8) for D þ E and D vs E,
respectively], a signiﬁcant treatment effect was not seen (P ¼ 0.24).Associations between total and regional fat mass and inﬂammation
Table III presents log-adjusted parameter estimates of the as-
sociation between several measures of baseline adiposity and
inﬂammation. Based on the magnitude of fat volume observed in
Table II, CT-derived measures of adiposity are presented per
1000 cm3. Lower total body mass, BMI, total body fat mass, and
percent body fat were signiﬁcantly associated with lower levels of
CRP and IL-6 (all P < 0.01); further, all regional fat depots (save
Fig. 2. Mean log-CRP by group across the 18-month intervention.
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muscular fat volume and CRP) were directly associated with log-
adjusted CRP and IL-6 parameter estimates (all P  0.04). After
adjustment for total body fat mass, only associations between log-
adjusted IL-6 and abdominal visceral fat volume (b ¼ 0.12 (95% CI:
0.03, 0.21) log pg/mL per 1000 cm3; P ¼ 0.02) and thigh inter-
muscular fat volume (b ¼ 8.34 (95% CI: 3.12, 13.56) log mg/L per
1000 cm3; P < 0.01) remained. AIC analysis for individuals with
baseline weight, BMI, DXA, and CT measures (n ¼ 162) suggest
models containing total body mass and global measures of
adiposity provide a better ﬁt than models containing regional fat
measures (lowest AIC found for BMI).
Associations between change in log-adjusted CRP and IL-6 per
unit change in measures of body and fat mass for participants un-
dergoing intentional weight loss (D and D þ E arms, only) are
presented in Table IV. Reductions in all measures of body fat mass
and distribution, save change in thigh intermuscular fat volume,
were associated with signiﬁcant reductions in CRP (all P  0.02);
and, loss of total and abdominal fat, but not thigh fat, were asso-
ciated with signiﬁcant reductions in IL-6 (all P  0.05). Only asso-
ciations between change in total, visceral, and subcutaneous
abdominal fat volume remained after further adjustment for
change in total body fat mass (all P  0.02, except the association
between IL-6 and abdominal visceral fat volume; P ¼ 0.07). Similar
to baseline ﬁndings, AIC analysis (n ¼ 98) revealed change in CRP
and IL-6 models containing change in global measures of adiposity
yielded the best ﬁt.
Lastly, a 5% reduction in baseline weight (selected a priori and
considered clinically meaningful21) was utilized as a referent point
to compare adjusted OR and 95% CI for achieving clinically desirableTable III
Log-adjusted parameter estimates and 95% conﬁdence intervals of the association betwe
Baseline body mass and adiposity measures Log-adjusted CRP (mg/L)
Estimate 95% CI
Total body mass (kg) 0.02 (0.01, 0.03)
BMI (kg/m2) 0.09 (0.06, 0.11)
Total body fat mass (kg) 0.04 (0.03, 0.06)
Percent body fat (%) 0.08 (0.06, 0.11)
Total abdominal fat volume (per 1000 cm3) 0.12 (0.04, 0.20)
Abdominal visceral fat volume (per 1000 cm3) 0.20 (0.05, 0.36)
Abdominal subcutaneous fat volume (per 1000 cm3) 0.14 (0.02, 0.26)
Abdominal intermuscular fat volume (per 1000 cm3) 0.85 (0.76, 2.46)
Total thigh fat volume (per 1000 cm3) 0.78 (0.13, 1.43)
Thigh intermuscular fat volume (per 1000 cm3) 4.96 (3.85, 13.76
Thigh subcutaneous fat volume (per 1000 cm3) 0.79 (0.12, 1.45)
Models are adjusted for randomization group, race, gender and age. CT-derived measure
* AIC estimates are calculated among participants with baseline weight, BMI, DXA, anlevels of CRP (<3.0 mg/L) and IL-6 (<2.5 pg/mL). Five percent
weight loss for D þ E and D participants was strongly associated
with improvement in the odds of achieving CRP <3.0mg/L [OR (95%
CI): 3.7 (1.7, 8.0)] and IL-6 <2.5 pg/mL [2.4 (1.2, 4.8)] (Fig. 3), with
similar results observed in analyses containing all groups:
CRP<3.0 mg/L [3.3 (1.8, 6.1)] and IL-6 <2.5 pg/mL [2.1 (1.2, 3.6)]. A
nearly identical relationship was observed for fat mass, with the
odds of achieving clinically desirable levels of CRP and IL-6 more
than doubling with 5% loss of fat mass.Discussion
The purpose of this study was to determine the association
between the magnitude of total body and regional fat loss and
reduction of systemic levels of CRP and IL-6 in overweight and
obese, older adults with knee OA partaking in an intensive lifestyle-
based weight loss intervention. Reductions in all measures of body
fat mass and distribution were associated with signiﬁcant re-
ductions in CRP, while only loss of total and abdominal (not thigh)
fat was associated with reduced IL-6. Although associations be-
tween loss of abdominal fat and reduced inﬂammation were in-
dependent of total adiposity, goodness of ﬁt analysis suggests loss
of total body mass and fat mass may be better predictors. Impor-
tantly, results from this study show that the odds of achieving
clinically desirable levels of CRP and IL-6 in this population more
than doubles with achievement of 5% loss of total body or fat mass.
Although the exact role of inﬂammation in the OA disease
pathway is debatable (i.e., a causal mediator22 or downstream
consequence23), evidence suggesting overall health detriment
associated with chronically elevated inﬂammatory biomarkers in
old age is much clearer. Several prospective studies provide
compelling data linking modest elevations in CRP to incident
CVD24e26, especially for individuals with CRP concentration
>3.0 mg/L (compared to those below 1.0 mg/L)17. Although IL-6
does not yet garner the same clinical importance as CRP, longitu-
dinal data from the Health ABC cohort (community-dwelling
adults; 70e79 years at baseline) suggest IL-6 may be a better pre-
dictor of cardiovascular morbidity27 and mortality28 than CRP. El-
evations in IL-6 are also associated with poor physical performance
and muscle strength29, and plasma levels greater than 2.5 pg/mL
are predictive of disability onset18. For these reasons, along with a
direct role inﬂammation may play in OA progression, efforts to
reduce chronically elevated CRP and IL-6 in this population below
3.0 mg/L and 2.5 pg/mL, respectively, appear prudent. Importantly,
we demonstrate here that the magnitude of sustained weight and
fat loss achieved in participants randomized to dietary-induced
weight loss in the IDEA study is signiﬁcantly associated withen baseline adiposity measures and baseline inﬂammation
Log-adjusted IL-6 (pg/mL)
P-value AIC* Estimate 95% CI P-value AIC*
<0.01 496.0 0.01 (0.01, 0.02) <0.01 303.5
<0.01 482.8 0.048 (0.03, 0.06) <0.01 293.1
<0.01 490.7 0.02 (0.01, 0.03) <0.01 299.9
<0.01 487.5 0.03 (0.02, 0.05) <0.01 300.3
<0.01 504.6 0.08 (0.04, 0.13) <0.01 311.5
0.01 504.7 0.17 (0.09, 0.25) <0.01 308.3
0.03 507.5 0.07 (0.00, 0.14) 0.04 318.3
0.30 505.9 1.37 (0.50, 2.23) <0.01 307.8
0.02 504.3 0.46 (0.10, 0.82) 0.01 313.7
) 0.27 502.0 9.60 (4.95, 14.25) <0.01 295.5
0.02 504.4 0.43 (0.06, 0.79) 0.02 314.7
s of adiposity are expressed per 1000 cm3.
d CT measures (n ¼ 162).
Table IV
18-month changes in log-adjusted inﬂammatory biomarker parameter estimates and 95% conﬁdence intervals, per unit change in measures of body adiposity, for individual
undergoing intentional weight loss, only
Change in body mass and adiposity measures D Log-adjusted CRP (mg/L) D Log-adjusted IL-6 (pg/mL)
Estimate 95% CI P-value AIC* Estimate 95% CI P-value AIC*
D Total body mass (kg) 0.05 (0.03, 0.06) <0.01 266.7 0.02 (0.01, 0.02) <0.01 184.0
D BMI (kg/m2) 0.15 (0.11, 0.19) <0.01 265.3 0.05 (0.03, 0.08) <0.01 182.2
D Total body fat mass (kg) 0.06 (0.04, 0.08) <0.01 271.2 0.02 (0.01, 0.04) <0.01 181.3
D Percent body fat (%) 0.08 (0.05, 0.11) <0.01 276.8 0.03 (0.01, 0.05) <0.01 182.9
D Total abdominal fat volume (per 1000 cm3) 0.37 (0.24, 0.51) <0.01 271.1 0.19 (0.11, 0.28) <0.01 191.4
D Abdominal visceral fat volume (per 1000 cm3) 0.79 (0.50, 1.08) <0.01 269.7 0.35 (0.15, 0.55) <0.01 193.3
D Abdominal subcutaneous fat volume (per 1000 cm3) 0.57 (0.33, 0.80) <0.01 276.5 0.33 (0.18, 0.48) <0.01 189.2
D Abdominal intermuscular fat volume (per 1000 cm3) 5.00 (0.66, 9.34) 0.02 284.8 2.75 (0.02, 5.49) 0.05 191.0
D Total thigh fat volume (per 1000 cm3) 0.88 (0.26, 1.49) <0.01 288.1 0.21 (0.20, 0.61) 0.31 195.4
D Thigh intermuscular fat volume (per 1000 cm3) 6.31 (4.14, 16.76) 0.23 286.9 3.61 (2.99, 10.20) 0.28 189.7
D Thigh subcutaneous fat volume (per 1000 cm3) 0.94 (0.29, 1.59) <0.01 287.8 0.21 (0.21, 0.64) 0.32 195.3
Results presented for the D and D þ E arms, only. Model estimates adjust for randomization group, race, gender, age and baseline outcome measure. CT-derived measures of
adiposity are expressed per 1000 cm3.
* AIC estimates are calculated among participants with baseline and follow-up weight, BMI, DXA, and CT measures (n ¼ 98).
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to confer cardioprotective and functional beneﬁt.
Data presented here conﬁrm and extend prior work suggesting a
direct relationship betweenweight and fat mass loss and decreased
inﬂammation11e13. Previous data also suggest a signiﬁcant role for
ectopic fat depots in the production of inﬂammatory cytokines15,
particularly in the abdominal cavity30. In accordance, our data show
abdominal fat loss is associated with reduced inﬂammation, inde-
pendent of total body fat mass. Loss of total bodymass and fat mass,
however, were found to explain more of the variability surrounding
change in inﬂammation than loss of regional fat volume, likely
driven by differential magnitude of change in these depots. This is
not to say that downstream health effects of regional fat are
inconsequential when compared to total body fat. On the contrary,
several studies show increased regional, and in particular, ectopic
fat stores are independently associated with increased risk of car-
diometabolic31,32 and physical33,34 dysfunction. Indeed, recently
published data from this study link thigh, but not total body, fat to
the external knee abduction moment35. Moreover, partitioning of
general body obesity into abdominal and thigh compartments
revealed that thigh fat had similar signiﬁcant associations with
knee joint forces as abdominal fat, despite its much smaller volume.Fig. 3. Adjusted odds ratios (OR) and 95% conﬁdence interval (CI) comparisons of achievingTo further this point, data from the Health ABC cohort show that
both high and increasing thigh intermuscular fat area are important
predictors of gait speed decline, independent of change in total
body fat mass34. Thus, clinical effects of fat mass location are likely
outcome speciﬁc, and true delineation of the effects of regional vs
total body fat mass loss on inﬂammatory biomarkers necessitates
results from a weight loss trial explicitly designed to test this
question.
The current study capitalizes on previously collected total and
regional adiposity data generated from a large, 18-month lifestyle-
based intervention that achieved signiﬁcant weight and fat mass
loss in a group of individuals presenting with subclinical inﬂam-
mation. Additional strengths include serial measures of two robust
biomarkers of inﬂammation in old age, as well use as sophisticated
statistical techniques to clarify which adiposity measures are most
associated with CRP and IL-6. This study is not without weaknesses,
however. Although the reduction in sample size from baseline to
18-monthswas assumed to be random, the potential for differential
drop out may have biased our results. The cut-points we used to
deﬁne a clinically meaningful threshold for inﬂammatory bio-
markers, while empirically driven, are not standardized and se-
lection of different cut-points (or inﬂammatory biomarkers), mayclinically desirable inﬂammation levels with 5% weight and fat mass loss, respectively.
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groups may be limited, as our study sample was represented pri-
marily by overweight and obese, Caucasian women with OA. Our
statistical approach attempted to include covariates parsimoni-
ously; particularly we included variables that were relevant to the
study design or known predictors of study outcomes. Thus, we
cannot rule out the possibility that the addition of some covariates
or exclusion of others may have led to bias in the observed asso-
ciations36. Lastly, CT-derived images were only available on a subset
of participants compared to the entire IDEA study sample.
In conclusion, diet-induced reductions in body and fat mass
predict reduction of CRP and IL-6, with models of global adiposity
found to provide the best ﬁt. Additionally, the odds of achieving
clinically desirable levels of inﬂammation more than double with
5% loss of body and fat mass. Future RCTs should be speciﬁcally
designed to identify the exact amount and location of fat mass loss
necessary to achieve clinically desirable levels of inﬂammation
across varied chronic conditions in older adults, and discern how
such reductions translate into risk of future disability, morbidity,
and mortality.
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